Home Cart Sign in  
Chemical Structure| 443104-02-7 Chemical Structure| 443104-02-7

Structure of CDDO-Im
CAS No.: 443104-02-7

Chemical Structure| 443104-02-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CDDO-Im is a synthetic triterpenoid more potent than its parent compound CDDO both in vitro and in vivo and a PPARγ agonist.

Synonyms: CDDO-Imidazolide; TP-235; CDDO Im, CDDO-Im

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CDDO-Im

CAS No. :443104-02-7
Formula : C34H43N3O3
M.W : 541.72
SMILES Code : CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CCC(C)(C[C@@]3([H])[C@]24[H])C)C(N5C=CN=C5)=O)C)6C)C(C(C#N)=C[C@]1(C)C6=CC4=O)=O
Synonyms :
CDDO-Imidazolide; TP-235; CDDO Im, CDDO-Im
MDL No. :MFCD12756341
InChI Key :ITFBYYCNYVFPKD-FMIDTUQUSA-N
Pubchem ID :9958995

Safety of CDDO-Im

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
CDDO-Im (RTA-403) functions as an activator of Nrf2 and PPAR, showing high affinity for PPARα and PPARγ with inhibition constants (Kis) of 232 nM and 344 nM, respectively[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
primary neurons 100 nM overnight CDDO-Im pretreatment significantly reduced LDH release and maintained Alamar blue fluorescence, indicating that CDDO-Im attenuated neuronal injury. PMC3335928
primary neurons 100 nM 2 and 6 h CDDO-Im treatment increased Nrf2 levels in nuclei and was accompanied by increased expression of HO-1. PMC3335928
primary neurons 50-300 nM 6 h CDDO-Im treatment resulted in 8-fold HO-1 upregulation in cultured neurons and protected against OGD. PMC3335928
alveolar type II epithelial cells 5 and 25 nM 6 h CDDO-Im strongly induced the expression of Gclc, Nqo1, and Gpx2 in Nrf21/1 cells but failed to stimulate these genes in Nrf22/2 cells. PMC2773914
RAW264.7 cells 0.1, 1.0, or 2.0 μM 24 h Reduced IFNα4-stimulated CD169 and PDCA-1 expression PMC7718430
RAW264.7 cells 0.5 μM 6 h Enhanced expression of Gpx4, Sod2, and Gclc PMC7718430
primary hepatocytes 200 μM 4 h To evaluate the protective effect of CDDO-Im on H/R-induced hepatocyte injury, results showed CDDO-Im pretreatment significantly reduced LDH release, decreased cleaved caspase-3 levels, and increased Bcl2 and Bcl-xl expression. PMC5596572
ARPE-19 cells 100 nM 24 h CDDO-Im enhanced the expression of GCLM, HO-1, and NQO1 and attenuated the CSE-induced expression of C3, C5, and CFB mRNA PMC4006310
primary human chondrocytes 20 nM 24 h CDDO-Im significantly alleviated TNF-α-induced apoptosis and extracellular matrix degradation in chondrocytes PMC9253092
iMycEμ-2 cells 1 μM 24 h CDDO-Im caused growth arrest and apoptosis, associated with a decrease in Myc protein PMC1553469
iMycEμ-1 cells 0.4 μM 24 h CDDO-Im caused growth arrest and apoptosis, associated with a decrease in Myc protein PMC1553469

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Global ischemia model Intracerebroventricular (ICV) infusion 0.5-1.5 μg Single injection CDDO-Im treatment augmented HO-1 expression in hippocampal neurons and resulted in significant increases in CA1 neuronal survival after global ischemia. PMC3335928
Mice Hyperoxia-induced acute lung injury model Oral 30 μM/kg Every 24 hours for 72 hours CDDO-Im significantly attenuated hyperoxia-induced acute lung injury, as evidenced by reduced alveolar protein leakage and neutrophil accumulation. This protective effect was accompanied by increased levels of Nrf2-regulated cytoprotective gene expression and reduced levels of DNA damage in the lung. PMC2773914
Mice Keap1FA/FA mouse model Intraperitoneal injection 10 μM/kg Once daily for 7 days CDDO-Im significantly increased angiotensin II-induced proteinuria, a phenomenon not observed in Nrf2 knockout mice. PMC7785672
Mice Pristane-induced lupus model Intraperitoneal injection 2.5 mg/kg Every other day for 14 days Decreased CM proportion, reduced Ifnar1 expression and ISG expression PMC7718430
Mice Sickle cell disease model mice Oral 20 μM/kg Three times per week for 19 days CDDO-Im ameliorates inflammation and organ damage by activating Nrf2, improving symptoms in sickle cell disease model mice. PMC4593117
Mice Liver ischemia-reperfusion injury model Intraperitoneal injection 2 mg/kg Single dose 3 hours before ischemia To evaluate the protective effect of CDDO-Im on liver ischemia-reperfusion injury, results showed CDDO-Im pretreatment significantly reduced hepatic necrosis and apoptosis, decreased ROS levels and inflammatory responses, improved mitochondrial dysfunction, and enhanced autophagy by activating the Nrf2/HO-1 pathway. PMC5596572
C57BL/6 male mice Osteoarthritis model induced by destabilization of medial meniscus (DMM) Intraperitoneal injection 2.5 mg/kg Every other day for 8 weeks CDDO-Im effectively reduced knee joint cartilage erosion and serum levels of inflammatory cytokines IL-1β and IL-6 PMC9253092
BALB/c.iMycEμ mice Plasmacytoma model Intraperitoneal injection 100 μg/50 μl Three times per week for 60 days CDDO-Im inhibits the development of plasmacytomas PMC1553469

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.85mL

0.37mL

0.18mL

9.23mL

1.85mL

0.92mL

18.46mL

3.69mL

1.85mL

References

 

Historical Records

Categories